资讯
Selumetinib's approval now includes children as young as 1 year old with NF1 and symptomatic, inoperable plexiform neurofibromas. The drug targets the RAS/MEK/ERK pathway, providing a non-surgical ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果